Agile Therapeutics Inc (AGRX) Expected to Announce Earnings of -$0.11 Per Share

Brokerages forecast that Agile Therapeutics Inc (NASDAQ:AGRX) will post earnings per share of ($0.11) for the current quarter, according to Zacks. Zero analysts have issued estimates for Agile Therapeutics’ earnings, with estimates ranging from ($0.13) to ($0.09). Agile Therapeutics reported earnings per share of ($0.16) during the same quarter last year, which suggests a positive year-over-year growth rate of 31.3%. The company is scheduled to issue its next earnings results on Friday, August 2nd.

According to Zacks, analysts expect that Agile Therapeutics will report full-year earnings of ($0.49) per share for the current financial year, with EPS estimates ranging from ($0.64) to ($0.39). For the next year, analysts expect that the business will report earnings of ($0.50) per share, with EPS estimates ranging from ($0.76) to $0.11. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that follow Agile Therapeutics.

Agile Therapeutics (NASDAQ:AGRX) last announced its earnings results on Thursday, May 2nd. The specialty pharmaceutical company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02).

A number of research analysts have commented on the stock. ValuEngine upgraded shares of Agile Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday. Maxim Group reiterated a “buy” rating and set a $3.00 price objective on shares of Agile Therapeutics in a research note on Friday, May 17th. Finally, Janney Montgomery Scott assumed coverage on shares of Agile Therapeutics in a research note on Friday, April 12th. They set a “buy” rating and a $4.00 price objective on the stock.

In related news, CEO Alfred Altomari acquired 25,000 shares of Agile Therapeutics stock in a transaction on Monday, March 25th. The shares were purchased at an average cost of $1.54 per share, for a total transaction of $38,500.00. Following the purchase, the chief executive officer now directly owns 238,568 shares of the company’s stock, valued at approximately $367,394.72. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Abhijeet J. Lele acquired 20,000 shares of Agile Therapeutics stock in a transaction on Friday, March 29th. The shares were bought at an average price of $1.54 per share, for a total transaction of $30,800.00. Following the completion of the purchase, the director now directly owns 37,949 shares in the company, valued at $58,441.46. The disclosure for this purchase can be found here. Corporate insiders own 8.50% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of AGRX. Perceptive Advisors LLC bought a new position in Agile Therapeutics during the 1st quarter valued at $12,724,000. Renaissance Technologies LLC lifted its position in shares of Agile Therapeutics by 54.3% in the 3rd quarter. Renaissance Technologies LLC now owns 1,223,897 shares of the specialty pharmaceutical company’s stock worth $449,000 after buying an additional 430,907 shares during the last quarter. Acadian Asset Management LLC lifted its position in shares of Agile Therapeutics by 260.7% in the 4th quarter. Acadian Asset Management LLC now owns 313,047 shares of the specialty pharmaceutical company’s stock worth $180,000 after buying an additional 226,255 shares during the last quarter. Advisor Group Inc. lifted its position in shares of Agile Therapeutics by 716.7% in the 1st quarter. Advisor Group Inc. now owns 147,000 shares of the specialty pharmaceutical company’s stock worth $222,000 after buying an additional 129,000 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Agile Therapeutics by 24.0% in the 4th quarter. Geode Capital Management LLC now owns 230,496 shares of the specialty pharmaceutical company’s stock worth $132,000 after buying an additional 44,639 shares during the last quarter. Hedge funds and other institutional investors own 21.59% of the company’s stock.

Shares of AGRX stock opened at $1.41 on Friday. The firm has a market capitalization of $62.12 million, a PE ratio of -2.43 and a beta of 0.45. The company has a quick ratio of 8.91, a current ratio of 8.91 and a debt-to-equity ratio of 0.01. Agile Therapeutics has a twelve month low of $0.23 and a twelve month high of $1.70.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch, which completed Phase III clinical trials.

Further Reading: Google Finance

Get a free copy of the Zacks research report on Agile Therapeutics (AGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.